Skip to content
★ Sign in to follow
QB

Qinghai Biotech Pharmaceutical Group Ltd. Stock: price and insider trades · Hong Kong

HK·Mcap HK$151.3MHealth Care

No insider purchase over the last 90 days. The latest, by WU Tianyu, was filed 14 Dec 2022.

Qinghai Biotech Pharmaceutical Group Ltd.: what insiders have been doing

Qinghai Biotech Pharmaceutical Group Ltd. belongs to the Health Care sector. Filings by its managers are published through HKEX. Nothing new has been filed by managers of Qinghai Biotech Pharmaceutical Group Ltd. in twelve months, the latest record being from 23 January 2025.

The full history, which starts in 2019, counts 11 purchases against 2 sales.

In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.

Insider Decl.
17
Thresholds
n/a
Buy Volume
€6M
11 ops. · all time
Sell Volume
n/a
2 ops. · all time

Since the insiders bought

  • Filed 14 Dec 2022 · 1425 days ago · €125k
    -50.0%
    Entry HK$3.80 · Close at T+365 HK$1.90
  • Filed 23 Jul 2020 · 2299 days ago · €131k
    +101.4%
    Entry HK$7.20 · Close at T+365 HK$14.50
  • Filed 23 Jul 2020 · 2299 days ago · €131k
    +101.4%
    Entry HK$7.20 · Close at T+365 HK$14.50

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 25,754 of 26,897 companies
14.4
score / 100
Value
7
Quality
22
FCF yld-39%
Earn yld-31%
EV/EBITDA·
ROE-72%
Gross mgn36%
Net mgn-34%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$1.46
Analyst consensus
·
Income statement
RevenueHK$139.1M
Gross profitHK$50.6M36% margin
EBITDA-HK$33.4M-24% margin
Net income-HK$46.7M-115.9% margin
Valuation
Beta1.10
Balance sheet & cash
Market capHK$151.3M
Total debtHK$13.5M
Free Cash Flow-HK$58.4M
Profitability & ownership
ROE-71.8%
ROA-4.8%
% insiders56.9%
% institutions0.0%
Last declaration on 23 January 2025
Declarations17 total
  • ●
    DirectorExecutives
    0HKEX
    308,000,000 sharesShareXHKGHKEX:DA20250123E00555
  • ●
    DirectorExecutives
    0HKEX
    00ShareXHKGHKEX:DA20241113E00322
  • ●
    DirectorExecutives
    0HKEX
    00ShareXHKGHKEX:DA20241113E00361
  • ▲
    DirectorExecutives
    995,200 HKD11HKEX
    12,440,000 shares@ HK$0.083.3% of flowShareXHKGHKEX:DA20221214E00273
    Canonical exit: 16 Oct 2022 (T+90)
  • ●
    DirectorExecutives
    1M HKD16HKEX
    6,000,000 shares@ HK$0.19649.0% of flowShareXHKGHKEX:DA20210309E00401
  • ▲
    DirectorExecutives
    1M HKD37HKEX
    6,000,000 shares@ HK$0.196100.0% of flowShareXHKGHKEX:DA20200723E00161
    Canonical exit: 20 Oct 2020 (T+90)
  • ▲
    DirectorExecutives
    2M HKD30HKEX
    10,000,000 shares@ HK$0.1965.8% of flowShareXHKGHKEX:DA20200723E00115
    Canonical exit: 20 Oct 2020 (T+90)
  • ▲
    DirectorExecutives
    4M HKD30HKEX
    20,000,000 shares@ HK$0.19611.7% of flowShareXHKGHKEX:DA20200723E00117
    Canonical exit: 20 Oct 2020 (T+90)
  • ▲
    DirectorExecutives
    1M HKD34HKEX
    6,000,000 shares@ HK$0.19651.0% of flowShareXHKGHKEX:DA20200723E00220
    Canonical exit: 20 Oct 2020 (T+90)
  • ▲
    DirectorExecutives
    10M HKD37HKEX
    50,000,000 shares@ HK$0.196100.0% of flowShareXHKGHKEX:DA20200723E00177
    Canonical exit: 20 Oct 2020 (T+90)
  • ▲
    DirectorExecutives
    1M HKD37HKEX
    6,000,000 shares@ HK$0.196100.0% of flowShareXHKGHKEX:DA20200723E00195
    Canonical exit: 20 Oct 2020 (T+90)
  • ▲
    DirectorExecutives
    8M HKD37HKEX
    40,000,000 shares@ HK$0.196100.0% of flowShareXHKGHKEX:DA20200723E00158
    Canonical exit: 20 Oct 2020 (T+90)
  • ▼
    DirectorExecutives
    0HKEX
    74,070,000 sharesShareXHKGHKEX:DA20200723E00116
  • ▼
    DirectorExecutives
    0HKEX
    74,070,000 sharesShareXHKGHKEX:DA20200723E00114
  • ▲
    DirectorExecutives
    25,398 HKD31HKEX
    170,000 shares@ HK$0.1494100.0% of flowShareXHKGHKEX:DA20200406E00441
    Canonical exit: 30 Jun 2020 (T+90)
  • ▲
    DirectorExecutives
    25,398 HKD31HKEX
    170,000 shares@ HK$0.1494100.0% of flowShareXHKGHKEX:DA20200406E00450
    Canonical exit: 30 Jun 2020 (T+90)
  • ▲
    DirectorExecutives
    26M HKD19HKEX
    145,000,000 shares@ HK$0.1879.1% of flowShareXHKGHKEX:DA20190722E00291
    Canonical exit: 20 Sept 2019 (T+90)

17 of 17 declarations

About Qinghai Biotech Pharmaceutical Group Ltd.

Qinghai Biotech Pharmaceutical Group Ltd. is a company involved in the development and manufacturing of pharmaceutical products in China. It is listed on the Hong Kong Stock Exchange.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations